Expert Review of Anticancer Therapy最新文献_第2页

Implementation of a CAR-T cell therapy program in India. 在印度实施CAR-T细胞治疗项目。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-05-08 DOI: 10.1080/14737140.2025.2501744

Hema Hotchandani, Manju Sengar, Alok Shetty, Anupa John, Atharva Karulkar, Devanshi Kalra, Smrithi Ravikumar, Anjali Jaiswal, Yuktam Yadav, Sugandha Parkar, Anuradha Walawalkar, Sonali Kadam, Bhausaheb Bagal, Lingaraj Nayak, Rahul Purwar, Hasmukh Jain

{"title":"Implementation of a CAR-T cell therapy program in India.","authors":"Hema Hotchandani, Manju Sengar, Alok Shetty, Anupa John, Atharva Karulkar, Devanshi Kalra, Smrithi Ravikumar, Anjali Jaiswal, Yuktam Yadav, Sugandha Parkar, Anuradha Walawalkar, Sonali Kadam, Bhausaheb Bagal, Lingaraj Nayak, Rahul Purwar, Hasmukh Jain","doi":"10.1080/14737140.2025.2501744","DOIUrl":"https://doi.org/10.1080/14737140.2025.2501744","url":null,"abstract":"Introduction: CAR-T cell therapy has changed the treatment paradigm for hematological malignancies, offering a curative potential for patients with relapsed or refractory disease. India, with its significant burden of hematological malignancies, faces unique challenges in implementing this therapy. The development of indigenous CAR-T cells has reduced costs substantially, but barriers remain, including limited manufacturing capacity, relatively high costs, and logistical constraints.Areas covered: This article emphasizes the importance of optimized patient selection and triaging of apheresis slots to maximize the benefits of CAR-T cell therapy. The use of efficient bridging therapies and antibody-based approaches are being explored to improve outcomes, particularly in aggressive lymphomas and leukemias. Opportunities lie in leveraging India's growing biotechnology sector for cost-efficient production and in evaluating novel combination therapies to enhance CAR-T cell efficacy. This article also explores the technical and socioeconomic challenges of CAR-T cell development in India and suggests strategies to enhance accessibility, affordability, and implementation.Expert opinion: Ongoing advancements and research may help tailor CAR-T cell protocols to the local population. Future integration of NK cell therapy, TCR-based approaches, and multi-antigen targeting holds promise for enhancing therapeutic efficacy.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-10"},"PeriodicalIF":2.9,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vitamins and dietary supplements in cancer treatment: is there a need for increased usage? 维生素和膳食补充剂在癌症治疗中的应用：是否需要增加使用量？

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-05-07 DOI: 10.1080/14737140.2025.2501077

Teresa Esposito, Francesca Pentimalli, Antonio Giordano, Salvatore Cortellino

{"title":"Vitamins and dietary supplements in cancer treatment: is there a need for increased usage?","authors":"Teresa Esposito, Francesca Pentimalli, Antonio Giordano, Salvatore Cortellino","doi":"10.1080/14737140.2025.2501077","DOIUrl":"https://doi.org/10.1080/14737140.2025.2501077","url":null,"abstract":"Introduction: Vitamins are essential for homeostasis and proper functioning of organisms. These micronutrients prevent tumor onset by functioning as antioxidants and enzymatic cofactors involved in anti-stress and immune responses, modulating epigenetic regulators, and shaping the microbiota composition. Unbalanced diets and sedentary lifestyles contribute to obesity, associated with increasing cancer risk. Cancer patients often exhibit vitamin deficiencies due to chronic inflammation, anticancer therapies, and tumor-induced metabolic changes, leading to malnutrition and cachexia.Areas covered: This review critically analyzes preclinical and clinical studies, sourced from PubMed and ClinicalTrials.gov databases, that investigate the potential benefits of vitamin supplementation and dietary interventions, such as intermittent fasting and ketogenic diets, in mouse tumor models and cancer patients. This analysis elucidates the limitations of such interventions and suggests optimal dietary strategies to prevent cancer and enhance patients' quality of life and prognosis.Expert opinion: To date, clinical studies have found no substantial benefit of over-the-counter vitamin supplements and dietary interventions on cancer patients' health and prognosis. To prevent the spread of useless and potentially harmful products by the nutraceutical industry, establishing a regulatory authority is necessary to monitor and ensure product quality and validity before commercialization.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-24"},"PeriodicalIF":2.9,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The interplay between angiogenesis and cervical cancer: a comprehensive review. 血管生成与宫颈癌之间的相互作用：一个全面的综述。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-05-05 DOI: 10.1080/14737140.2025.2501073

Addrita Nandi, Arabinda Ghosh, Samir Kumar Sil

{"title":"The interplay between angiogenesis and cervical cancer: a comprehensive review.","authors":"Addrita Nandi, Arabinda Ghosh, Samir Kumar Sil","doi":"10.1080/14737140.2025.2501073","DOIUrl":"https://doi.org/10.1080/14737140.2025.2501073","url":null,"abstract":"Introduction: Cervical cancer is still a major global health threat, specifically in countries with little access to health services. Angiogenesis in cervical cancer not only contributes to tumor growth, metastasis, and resistance to therapy but also serves as a therapeutic target itself. This gives hope for the possible therapy.Areas covered: This review covers key molecular mechanisms in cervical cancer, including VEGF/VEGFR, HIF-1α, and PI3K/Akt pathways. It also discusses anti-angiogenic therapies like bevacizumab, small-molecule compounds, and emerging approaches such as nanoparticle-based drug delivery. Emphasis is placed on angiogenesis-related biomarkers for diagnosis and treatment selection, stressing the need for affordable therapies in low-resource settings. A literature search was conducted using PubMed, Scopus, and Google Scholar up to March 2025, focusing on VEGF/VEGFR signaling, anti-angiogenic therapies, and resistance mechanisms in cervical cancer.Expert opinion: Despite promise, resistance, toxicity, and cost remain major challenges for anti-angiogenic therapy's clinical use. Combination strategies with immunotherapy, chemotherapy, and targeted agents may be more effective. Precision medicine using multi-omics and AI offers hope for better outcomes. Future studies should evaluate drug combinations with synergistic effects and develop management strategies to universalize innovative treatments.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143994457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer. CDK4/6抑制剂剂量减少对绝经后HR+ her2阴性转移性乳腺癌患者生存的影响

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-05-01 Epub Date: 2025-04-10 DOI: 10.1080/14737140.2025.2490289

Furkan Ceylan, Safa Can Efil, Didem Şener Dede, Ates Kutay Tenekeci, Burak Bilgin, Şebnem Yücel, Eren Göktuğ Ceylan, Mutlu Hızal, Mehmet Ali Nahit Şendur, Muhammed Bülent Akıncı, Öznur Bal, Bülent Yalçın

{"title":"The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer.","authors":"Furkan Ceylan, Safa Can Efil, Didem Şener Dede, Ates Kutay Tenekeci, Burak Bilgin, Şebnem Yücel, Eren Göktuğ Ceylan, Mutlu Hızal, Mehmet Ali Nahit Şendur, Muhammed Bülent Akıncı, Öznur Bal, Bülent Yalçın","doi":"10.1080/14737140.2025.2490289","DOIUrl":"10.1080/14737140.2025.2490289","url":null,"abstract":"Background: This study aimed to evaluate the effect of dose reduction of CDK4/6 inhibitors on survival outcomes in postmenopausal patients with HR+HER2-negative metastatic breast cancer (mBC).Methods: A retrospective cohort study was conducted involving 164 postmenopausal patients with HR+ HER2-negative mBC who received CDK4/6 inhibitors between 2021 and 2024. Clinical parameters were systematically analyzed. Progression-free survival (PFS) and overall survival (OS) were evaluated based on dose reduction status. Survival outcomes were estimated using the Kaplan-Meier method, and independent prognostic factors were identified through multivariate Cox regression analysis.Results: The median age was 61 years, with a median follow-up of 23.5 months. The median PFS was 23.3 months, while median OS was not reached. Dose reduction occurred in 45 patients (27%), who exhibited significantly worse survival (PFS HR: 1.67, 95% CI: 1.02-2.72, p = 0.042; OS HR: 2.54, 95% CI:1.34-4.83, p = 0.004). Dose reduction and liver metastases were independent risk factors for shorter PFS and OS, while treatment in later lines was associated with shorter PFS.Conclusion: Dose reductions in CDK4/6 inhibitors were associated with worse survival outcomes in postmenopausal HR+ HER2- mBC patients. Future biomarker-driven studies are needed to guide personalized dose adjustments and optimize treatment efficacy.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"579-588"},"PeriodicalIF":2.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current and emerging treatment perspectives for adults with Waldenström macroglobulinemia. 成人Waldenström巨球蛋白血症的当前和新出现的治疗观点。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-05-01 Epub Date: 2025-04-03 DOI: 10.1080/14737140.2025.2488312

Alberto Guijosa, Shayna Sarosiek, Jorge J Castillo

{"title":"Current and emerging treatment perspectives for adults with Waldenström macroglobulinemia.","authors":"Alberto Guijosa, Shayna Sarosiek, Jorge J Castillo","doi":"10.1080/14737140.2025.2488312","DOIUrl":"10.1080/14737140.2025.2488312","url":null,"abstract":"Introduction: Waldenström Macroglobulinemia (WM) is distinguished from other indolent lymphomas by its unique molecular landscape and clinical behavior. With the emergence of new therapeutic options and improved survival rates, it has become increasingly important to balance the goal of prolonging survival with minimizing treatment-related toxicities.Areas covered: This review focuses on the current therapeutic strategies for WM, emphasizing the clinical effectiveness of various agents and treatment groups and their associated toxicity profiles. Additionally, we discuss emerging therapies and combinations, which have shown encouraging preliminary results.Expert opinion: WM remains an incurable disease, yet its indolent nature and the growing array of therapeutic options have significantly improved outcomes in first- and subsequent-line settings. Chemoimmunotherapy and BTK inhibitors have demonstrated high efficacy and durable responses, with the latter offering a stem-cell-sparing approach. However, unlike in CLL or multiple myeloma, evidence supporting the superiority of targeted agents over chemoimmunotherapy is not available. Consequently, treatment decisions depend on patient characteristics and shared decision-making to carefully balance risks, select appropriate regimens, and encourage clinical trial participation to advance in understanding this rare disease.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"485-497"},"PeriodicalIF":2.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges. 目前正在研究的雄激素受体拮抗剂治疗耐药前列腺癌：进展和挑战。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-05-01 Epub Date: 2025-03-20 DOI: 10.1080/14737140.2025.2481141

Linda Danielli, Elisa Tassinari, Andrea Marchetti, Matteo Rosellini, Veronica Mollica, Liang Cheng, Francesco Massari

{"title":"Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges.","authors":"Linda Danielli, Elisa Tassinari, Andrea Marchetti, Matteo Rosellini, Veronica Mollica, Liang Cheng, Francesco Massari","doi":"10.1080/14737140.2025.2481141","DOIUrl":"10.1080/14737140.2025.2481141","url":null,"abstract":"Introduction: Prostate cancer represents a significant oncological challenge, with its natural history predominantly driven by androgen receptor (AR) signaling. The pivotal role of this pathway underscores the rationale for targeting AR activity in therapeutic strategies. However, the development of resistance mechanisms has highlighted the need for advanced therapies to address the complexity of the castration-resistant status.Areas covered: We analyzed the evolving role of second-generation androgen receptor signaling inhibitors (ARSIs) in the management of non-metastatic and metastatic castration-resistant prostate cancer, we critically examine emerging combination strategies involving ARSIs, novel agents targeting resistance pathways, and the mechanisms underlying treatment resistance. The review also provides insights into future directions for enhancing outcomes. PubMed literature research using keywords related to castration-resistant prostate cancer and its treatments was performed, including the most relevant trials and reviews.Expert opinion: ARSIs have revolutionized the management of prostate cancer, providing substantial clinical benefits and representing the cornerstone of current treatment paradigms. However, key challenges remain, including determining optimal treatment sequencing, overcoming resistance mechanisms, and tailoring therapies to specific molecular subtypes. Biomarker-driven approaches are critical for refining patient selection and improving therapeutic outcomes. Ongoing trials investigating novel hormonal-axis-directed agents and innovative combination therapies aim to expand the arsenal of effective treatment.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"457-470"},"PeriodicalIF":2.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contemporary management of diffuse large B-cell lymphoma in Japan. 日本弥漫大b细胞淋巴瘤的当代治疗。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-05-01 Epub Date: 2025-04-08 DOI: 10.1080/14737140.2025.2490283

Katsuhiro Miura, Hiromichi Takahashi, Haruna Nishimaki-Watanabe, Takashi Hamada, Akihiro Uchiike, Daisuke Tsutsumi, Shimon Ohtake, Kazuhide Iizuka, Takashi Koike, Kazuya Kurihara, Toshihide Endo, Tatsuya Hayama, Masaru Nakagawa, Noriyoshi Iriyama, Yoshihiro Hatta, Hideki Nakamura

{"title":"Contemporary management of diffuse large B-cell lymphoma in Japan.","authors":"Katsuhiro Miura, Hiromichi Takahashi, Haruna Nishimaki-Watanabe, Takashi Hamada, Akihiro Uchiike, Daisuke Tsutsumi, Shimon Ohtake, Kazuhide Iizuka, Takashi Koike, Kazuya Kurihara, Toshihide Endo, Tatsuya Hayama, Masaru Nakagawa, Noriyoshi Iriyama, Yoshihiro Hatta, Hideki Nakamura","doi":"10.1080/14737140.2025.2490283","DOIUrl":"10.1080/14737140.2025.2490283","url":null,"abstract":"Introduction: Despite the heterogeneity of diffuse large B-cell lymphoma (DLBCL), treatment approaches are remarkably well-standardized. However, its management differs according to socio-economic and medical environments.Areas covered: This review analyzed the latest trends in DLBCL diagnosis and treatment in Japan, where the national universal healthcare insurance covers the cost of novel modalities, such as polatuzumab vedotin, chimeric antigen receptor T cells (CAR-T), or bispecific antibodies (BsAb). Given the particularly high incidence, we spotlighted DLBCL in older adults. CD5-positive (CD5+) DLBCL and intravascular large B-cell lymphoma (IVLBCL) were also discussed based on the leading trials conducted in Japan.Expert opinion: The accurate pathologic diagnosis of DLBCL made by experts or via consultation networks is essential, and an emerging genomic assay will contribute to future precision approaches. Although polatuzumab vedotin is frequently used in the first-line treatment of patients with advanced disease, its application should be carefully analyzed. As the number of older patients increases, the importance of pre-treatment geriatric assessment becomes apparent. CD5+ DLBCL and IVLBCL adopt distinct strategies with high-dose methotrexate, but their benefits warrant further evaluation. CAR-T and BsAb are increasingly used to treat patients with relapsed and refractory diseases. A cost-effective evaluation of these novel approaches is required.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"551-559"},"PeriodicalIF":2.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alternative regimen for chemotherapy-intolerant lymphoma including practical aspects in Japan. 化疗不耐受淋巴瘤的替代方案，包括日本的实践方面。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-05-01 Epub Date: 2025-04-06 DOI: 10.1080/14737140.2025.2488317

Akihiro Ohmoto, Shigeo Fuji

{"title":"Alternative regimen for chemotherapy-intolerant lymphoma including practical aspects in Japan.","authors":"Akihiro Ohmoto, Shigeo Fuji","doi":"10.1080/14737140.2025.2488317","DOIUrl":"10.1080/14737140.2025.2488317","url":null,"abstract":"Introduction: With the increasing number of elderly patients with lymphoma and the emergence of novel agents, clinical investigations for patients considered intolerant to conventional cytotoxic chemotherapy are receiving more focus than before.Areas covered: This review aims to provide an overview of systemic treatment for patients with lymphoma who are intolerant to conventional chemotherapy, including practical aspects in Japan.Expert opinion: Traditional approaches include dose reduction (e.g. mini-CHOP) or non-anthracycline regimens (e.g. CVP or bendamustine-based regimens) to reduce the risk of cardiotoxicity. A recent trend is the combination of molecular-targeted agents, such as lenalidomide plus rituximab in B-cell lymphoma. However, maintaining durable responses remains a major challenge. In the future, clinical trials in elderly or frail patients are expected to investigate novel agents such as antibody-drug conjugates or bispecific T-cell engagers. In addition, comprehensive geriatric assessment for tailored therapeutic intervention or dose optimization strategies based on individual genomic data is expected in the context of prospective studies.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"423-433"},"PeriodicalIF":2.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in liquid biopsy and virtual biopsy for care of patients with glioma: a narrative review. 液体活检和虚拟活检在胶质瘤患者护理中的进展：叙述性回顾。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-05-01 Epub Date: 2025-04-05 DOI: 10.1080/14737140.2025.2489629

Muhammad Awais, Abdul Rehman, Syed Sarmad Bukhari

{"title":"Advances in liquid biopsy and virtual biopsy for care of patients with glioma: a narrative review.","authors":"Muhammad Awais, Abdul Rehman, Syed Sarmad Bukhari","doi":"10.1080/14737140.2025.2489629","DOIUrl":"10.1080/14737140.2025.2489629","url":null,"abstract":"Introduction: The World Health Organization's 2021 classification of central nervous system neoplasms incorporated molecular and genetic features for classifying gliomas. Classification of gliomas located in deep-seated structures became a clinical conundrum given the absence of crucial pathological and molecular data. Advances in noninvasive imaging modalities offered virtual biopsy as a novel solution to this problem by identifying surrogate radiomic signatures. Liquid biopsies of blood or cerebrospinal fluid provided another enormous opportunity for identifying genomic, metabolomic and proteomic signatures.Areas covered: We summarize and appraise the current state of evidence with regards to virtual biopsy and liquid biopsy in the care of patients with gliomas. PubMed, Embase and Google Scholar were searched on 7/30/2024 for relevant articles published after the year 2013 in the English language.Expert opinion: A large body of preclinical and preliminary clinical evidence suggests that virtual biopsy is possible with the combined use of multiple novel imaging modalities in conjunction with machine learning and radiomics. Likewise, liquid biopsy in conjunction with focused ultrasound may be a valuable tool to obtain proteomic and genomic data regarding glioma in a minimally invasive manner. These modalities will likely become an integral part of care for patients with glioma in the future.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"529-550"},"PeriodicalIF":2.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143778939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Imetelstat in myeloid malignancies: current data and future directions. Imetelstat 在骨髓恶性肿瘤中的应用：当前数据和未来方向。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-05-01 Epub Date: 2025-03-28 DOI: 10.1080/14737140.2025.2482721

Aram Bidikian, Jan P Bewersdorf, Tariq Kewan, Nikolai A Podoltsev, Maximilian Stahl, Amer M Zeidan

{"title":"Imetelstat in myeloid malignancies: current data and future directions.","authors":"Aram Bidikian, Jan P Bewersdorf, Tariq Kewan, Nikolai A Podoltsev, Maximilian Stahl, Amer M Zeidan","doi":"10.1080/14737140.2025.2482721","DOIUrl":"10.1080/14737140.2025.2482721","url":null,"abstract":"Introduction: Telomerase reactivation allows cancer cells to maintain telomere length and evade senescence, making it an appealing therapeutic target. Imetelstat, an antisense oligonucleotide, is the first clinically effective telomerase inhibitor approved by the FDA and the European Commission for treating anemia in transfusion-dependent low-risk myelodysplastic syndromes (MDS).Areas covered: Sources for this review were identified through searches of PubMed, ClinicalTrials.gov, and conference abstracts. This review highlights the pharmacology, efficacy, and ongoing trials of imetelstat in treating MDS, myelofibrosis, essential thrombocythemia, and other malignancies. In the IMerge trial, imetelstat induced durable transfusion independence in heavily transfused LR-MDS patients. Pilot trials in myelofibrosis suggest imetelstat's potential disease-modifying properties and survival benefit, warranting further studies of imetelstat as a monotherapy or in combination therapies. Imetelstat can cause thrombocytopenia, leukopenia, elevated liver enzymes, and infusion reactions, which are mostly reversible but may rarely lead to fatal events.Expert opinion: Future clinical trials in LR-MDS should focus on optimal sequencing and combination strategies for imetelstat with other agents, and identifying biomarkers that can predict response. Monitoring real-world outcomes will offer valuable insights into imetelstat's safety and efficacy in patient populations underrepresented in clinical trials. Imetelstat's role in other malignancies, especially myelofibrosis, is being explored.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"517-528"},"PeriodicalIF":2.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0